⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 5, 2024Journal of the National Comprehensive Cancer Network

HSR24-170: Utilization of Biomarker Testing and Biomarker-Driven Targeted Therapy Among Patients With Metastatic Non–Small Cell Lung Cancer

Nicole Zhang Julie Wiedower Kaylor Karen M. Stockl Jacqueline K. Lekostaj Jamie Tucker Shaun P. Forbes Julia M. Certa Caroline Weipert Keelia Clemens Lucy R. Langer

View at Publisher

Ask AI

Bookmark

Share

Abstract

"HSR24-170: Utilization of Biomarker Testing and Biomarker-Driven Targeted Therapy Among Patients With Metastatic Non–Small Cell Lung Cancer" published on 05 Apr 2024 by National Comprehensive Cancer Network.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e70542b6db64358767eb99 https://doi.org/10.6004/jnccn.2023.7151

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1HSR24-161: Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients With Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–20232024
2Abstract 2552: Real-world analysis of biomarker testing and use of targeted therapies in metastatic non-small cell lung cancer (mNSCLC) in the United States (US)2024
3Biomarker testing and targeted therapy use among patients with non-small cell lung cancer in the United States: An analysis using a physician notes real-world database.2024
4The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast2024 · 7 citations
5Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesObservational Study · 2026

More related papers

Biomarker testing patterns and patient outcomes for metastatic NSCLC, CRC, and metastatic/recurrent HNSCC at Texas Oncology.2026
Abstract 3426: Real-world biomarker testing rates and trends among patients with advanced non-small cell lung cancer in the US2024
Biomarker testing for metastatic non-small cell lung cancer across Michigan Oncology Quality Consortium (MOQC) sites.2025

More from Journal of the National Comprehensive Cancer Network

Care Outcomes Among Hospitalized Patients With Cancer: A Retrospective Cohort StudyTue,
Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective StudyTue,